financetom
Business
financetom
/
Business
/
American Vanguard Q3 revenue, profit miss estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Vanguard Q3 revenue, profit miss estimates
Nov 10, 2025 5:35 AM

Overview

* American Vanguard ( AVD ) Q3 revenue missed analyst expectations, net income also missed

* Adjusted EBITDA for Q3 rises to $8.2 mln from $1.8 mln last year

* Company maintains full-year 2025 EBITDA guidance of $40 mln to $44 mln

Outlook

* American Vanguard ( AVD ) maintains 2025 adjusted EBITDA guidance of $40 mln to $44 mln

* Company expects greater market stability as it heads into 2026

* Fourth quarter expected to be strongest, generating material free cash flow

Result Drivers

* MANUFACTURING EFFICIENCY - Improved manufacturing efficiency contributed to higher gross profit margins and increased EBITDA

* INVENTORY REDUCTION - Reduction in total inventory by $47 mln limited the need to access credit

* PRODUCT LIABILITY CHARGE - $7.6 mln charge for product liability claims included in adjusted EBITDA, with future recovery expected

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $119.31 $128 mln

Revenue mln (1

Analyst)

Q3 Net Miss -$12.36 -$2.35

Income mln mln (1

Analyst)

Q3 Miss -$6.51 $1.12

Operatin mln mln (1

g Income Analyst)

Q3 Gross $34.21

Profit mln

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the agricultural chemicals peer group is "buy"

* Wall Street's median 12-month price target for American Vanguard Corp ( AVD ) is $12.00, about 57.5% above its November 7 closing price of $5.10

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO on The Day, Week Ahead in Canada
BMO on The Day, Week Ahead in Canada
Jan 27, 2025
07:47 AM EST, 01/27/2025 (MT Newswires) -- Investors will get the advance reading on Canada's wholesale trade for December at 8:30 a.m. ET on Monday, noted Bank of Montreal (BMO). There's plenty to chew on later in the week, with the monthly real gross domestic product report for November out on Friday. The bank is looking for a 0.1% decline...
HEDGE FLOW-Hedge funds were pausing US AI bets as DeepSeek emerged, says Goldman
HEDGE FLOW-Hedge funds were pausing US AI bets as DeepSeek emerged, says Goldman
Jan 27, 2025
* Hedge funds reduce tech stock bets amid Chinese AI competition * Goldman Sachs ( GS ) notes hedge funds' reluctance to invest in U.S. tech sector * DeepSeek challenges U.S. AI dominance, raising investor concerns By Nell Mackenzie LONDON, Jan 27 (Reuters) - Hedge funds were already waiting to see if a U.S.-fostered, home-grown artificial intelligence boom would continue...
Discovery Silver to acquire Newmont's gold mining operations at Porcupine for $425M
Discovery Silver to acquire Newmont's gold mining operations at Porcupine for $425M
Jan 27, 2025
Jan 27 (Reuters) - Gold miner Discovery Silver ( DSVSF ) said on Monday it would acquire its peer Newmont's ( NEM ) stake in Porcupine Operations in Ontario, Canada, for $425 million. Newmont ( NEM ), after buying Australia-based Newcrest for $17.14 billion, announced in February 2024 it would divest non-core assets and trim its workforce to cut debt....
Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis
Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis
Jan 27, 2025
07:50 AM EST, 01/27/2025 (MT Newswires) -- Akero Therapeutics ( AKRO ) said Monday that a phase 2b study of its lead product candidate efruxifermin showed a statistically significant reversal of compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis, or MASH. The company said that among patients with baseline and week 96 biopsies, 39% of those treated with efruxifermin showed reversal...
Copyright 2023-2026 - www.financetom.com All Rights Reserved